EASL Podcasts

This episode aims at highlighting the importance of patient and public involvement in research. More precisely, the speakers focus on the importance of involving patients in research, practical steps to involve patients in research, and insights from EASL including engagement of patients in the EASL-Lancet Commission. Faculty Related episode United we stand: Global societies collaborating to beat liver disease.All EASL Studio Podcasts are available on EASL Campus.

This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm. Faculty This EASL Studio is supported by AstraZeneca. EASL has received no input from AstraZeneca with regards to the content of this programme. Related episodes Basics in decision-making for liver cancer treatmentHighlights of the liver cancer research at EASL Congress 2023Highlights from the EASL Liver Cancer Summit 2023A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceLiver cancer in 2022: Wrap-up & outlookTransplanting patients with cancer – Is there a limit?JHEP Live on the best animal model for HCC – Lost in translation?All EASL Studio Podcasts are available on EASL Campus.

In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs. Faculty This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). Related episodes Statins in cirrhosis: The window hypothesis again, or just a closed window?Liver cirrhosis in 2023: Unmet needs and how to address themAlbumin in Cirrhosis: For all, some, or none?Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies withinShould anticoagulants be given to patients with cirrhosis to improve outcome?Betablockers in cirrhosis: Has Baveno consensus gone too far?All EASL Studio Podcasts are available on EASL Campus.

This episode treats of the Hepahealth II study, which aimed at estimating the impact of policy interventions targeting alcohol and obesity on the incidence of chronic liver disease and primary liver cancer in three European countries. Join our experts in their discussion of this study and of its conclusions. Faculty Related episodes EASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio from EASL Congress 2023: The battle to reduce alcohol harms… EASL’s new policyEASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S2E2: Fats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.

On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field. Faculty Related episodes Clinical trials in rare diseases – opportunities and challengesRare Liver Diseases – A growing landscape of opportunities and challengesThis episode is scheduled in honour of the Rare Disease Day (29 February). All EASL Studio Podcasts are available on EASL Campus.

The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research? Faculty Related episodes JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approachSteatotic liver disease global consensus to change nomenclatureJHEP Live: Is the term ‘decompensated cirrhosis’ outdated?All EASL Studio Podcasts are available on EASL Campus.

In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead. Faculty This episode is scheduled in honour of the World CCA Day (15 February) and the US CCA Awareness Month. Related episodes Basics in decision-making for liver cancer treatmentHighlights of the liver cancer research at EASL Congress 2023Highlights from the EASL Liver Cancer Summit 2023A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceLiver cancer in 2022: Wrap-up & outlookTransplanting patients with cancer – Is there a limit?All EASL Studio Podcasts are available on EASL Campus.

The participants focus on the topic of managing recurrent bleeding due to small-intestinal angiodysplasia – a persistent challenge encountered by many hepatologists. Our panel explores effective treatments and interventions, including medications like bevacizumab and thalidomide, alongside the role of endoscopy in diagnosis and management. Faculty Related episodes: Should anticoagulants be given to patients with cirrhosis to improve outcomeAll EASL Studio Podcasts are available on EASL Campus.

Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists. Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management! Faculty This episode is scheduled following the United Kingdom’s National Obesity Awareness Week. Related episodes: Why bother with diet and exercise when an injection will suffice?The central role of alcohol and food policies on liver healthFats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.

Join us for a wrap-up of EASL Studio’s season and a preview of what is to come in 2024! In this special episode, we reminisce about the year’s top hepatology breakthroughs and controversies. This festive discussion highlights the best of the past while offering an exciting glimpse into the future of the evolving world of liver health. Faculty All EASL Studio Podcasts are available on EASL Campus.

Hepatic encephalopathy (HE) is a common reversible complication of advanced liver disease characterised by a spectrum of neuropsychiatric abnormalities. Due to its insidious onset, most patients only seek treatment once complications develop, resulting in it being an underdiagnosed and underestimated condition. This EASL Studio episode, organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN), explores the patient journey and treatment options. Faculty This EASL Studio is supported by Norgine. EASL has received no input from Norgine with regards to the content of this programme. Related episode JHEP Live on critical appraisal of classification, diagnosis and treatment of hepatic encephalopathyAll EASL Studio Podcasts are available on EASL Campus.

With cases of hepatocellular carcinoma on the rise and representing the end stage of many chronic liver diseases, the treatment of liver cancer has become one of the most dynamic areas in hepatology. The focus of this episode is on answering practical clinical questions, examining trial data, and sharing clinical insights that may be useful for decision-making in daily clinical practice. Faculty This EASL Studio is supported by AstraZeneca and Eisai. EASL has received no input from AstraZeneca or Eisai with regards to the content of this programme. Related episodes Highlights of the liver cancer research at EASL Congress 2023Highlights from the EASL Liver Cancer Summit 2023A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceLiver cancer in 2022: Wrap-up & outlookTransplanting patients with cancer – Is there a limit?All EASL Studio Podcasts are available on EASL Campus.

This episode explores key aspects of intriguing intersection of autoimmune liver diseases, such as their distinctive presentations in childhood and adulthood and the influence of inflammatory bowel disease on liver disease phenotypes. The speakers also examines the benefits and risks associated with immunosuppressive treatments in managing these complex conditions. Faculty This EASL Studio is supported by Chemomab Therapeutics. EASL has received no input from Chemomab Therapeutics with regards to the content of this programme. Related episodes PBC: the itch we need to scratchChallenges and opportunities for patients with PBC: Highlights from EASL Congress 2023Primary biliary cholangitis: a look at the future landscape of therapy for patientsAll EASL Studio Podcasts are available on EASL Campus.

The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis. Faculty This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme. Related episodes Liver cirrhosis in 2023: Unmet needs and how to address themAlbumin in Cirrhosis: For all, some, or none?JHEP Live: is the term ‘decompensated cirrhosis’ outdated?Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies withinAll EASL Studio Podcasts are available on EASL Campus.

In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases. Faculty This episode is scheduled according to the international calendar for the World Diabetes Day (14 November). This EASL Studio is supported by Boehringer Ingelheim and Novo Nordisk. EASL has received no input from Boehringer Ingelheim or Novo Nordisk with regards to the content of this programme. Related episodes: Bugs and the liver — the role of the gut microbiome in liver diseasesFats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.

In honour of the Awareness Week on Alcohol related harm (21 November – 1 December), this episode discussed how the new nomenclature will affect healthcare pathways for those suffering with Alcohol-related liver diseases. Faculty Related episodes: Steatotic liver disease global consensus to change nomenclatureThe central role of alcohol and food policies on liver healthJHEP Live: Stigma and alcoholAll EASL Studio Podcasts are available on EASL Campus.

Join the faculty as they take a deep dive into hepatitis delta (HDV) to: Faculty Related episodes: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitorTreatment of HBV-HDV coinfection in the era of entry inhibitionAll EASL Studio Podcasts are available on EASL Campus.

During this episode, the experts discuss of what it really takes to implement a successful lifestyle modification in behavioural therapy. Tune in to learn tools and tips that can help treat patients in improving their liver health and quality of life. This episode was scheduled according to the international calendar for the World Food Day (16 October) Faculty Related episodes The central role of alcohol and food policies on liver healthFats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.

This episode delves into the pervasive yet seldom-discussed issue of burnout, particularly prevalent in high-pressure fields like clinical medicine and competitive research. Fuelled by relentless ambition and a fear of falling short, professionals push themselves to the limit, often neglecting their own well-being. As the world grapples with a confluence of challenges including the ongoing pandemic, climate crisis, and geopolitical tensions, the need for self-care becomes more pressing than ever. Faculty Related Nature article by participant Kelly Korreck: How I managed my intense burnout This episode is scheduled according to the international calendar for the World Mental Health Day (10 October). All EASL Studio Podcasts are available on EASL Campus.

In this episode, the discussants examines the following questions, raised after a Journal of Hepatology’s nomenclature article: Faculty Related article A multi-society Delphi consensus statement on new fatty liver disease nomenclatureRelated episodes Steatotic liver disease global consensus to change nomenclatureAll EASL Studio Podcasts are available on EASL Campus.